{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:27Z","timestamp":1793037627279,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Health and Labour Sciences Research Grant on Intractable Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00415-021-10520-x","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T14:02:36Z","timestamp":1616853756000},"page":"3781-3788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long-term outcomes and prognostic factors in generalized myasthenia gravis"],"prefix":"10.1007","volume":"268","author":[{"given":"Yukiko","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1863","authenticated-orcid":false,"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Himuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"issue":"10","key":"10520_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/s1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"5","key":"10520_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475\u2013490. https:\/\/doi.org\/10.1016\/s1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"issue":"4","key":"10520_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/wnl.0000000000002790","journal-title":"Neurology"},{"issue":"2","key":"10520_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"issue":"5\u20136","key":"10520_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43(5\u20136):428\u2013435. https:\/\/doi.org\/10.3109\/08916930903518107","journal-title":"Autoimmunity"},{"issue":"6","key":"10520_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","volume":"55","author":"K Utsugisawa","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Murai H, Aoki M (2017) Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55(6):794\u2013801. https:\/\/doi.org\/10.1002\/mus.25397","journal-title":"Muscle Nerve"},{"issue":"1","key":"10520_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70(1):327\u2013334","journal-title":"Ann Thorac Surg"},{"key":"10520_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cen3.12180","volume":"6","author":"H Murai","year":"2015","unstructured":"Murai H (2015) Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol 6:21\u201331. https:\/\/doi.org\/10.1111\/cen3.12180","journal-title":"Clin Exp Neuroimmunol"},{"issue":"2","key":"10520_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, Shimizu Y, Utsumi H, Fujihara K, Uchiyama S, Suzuki N (2012) The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 46(2):166\u2013173. https:\/\/doi.org\/10.1002\/mus.23398","journal-title":"Muscle Nerve"},{"issue":"7","key":"10520_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489","journal-title":"Neurology"},{"issue":"1","key":"10520_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","volume":"1413","author":"H Murai","year":"2018","unstructured":"Murai H, Utsugisawa K, Nagane Y, Suzuki S, Imai T, Motomura M (2018) Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann N Y Acad Sci 1413(1):35\u201340. https:\/\/doi.org\/10.1111\/nyas.13544","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10520_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000322497","volume":"65","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Suzuki S, Suzuki N, Utsugisawa K (2011) Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 65(1):16\u201322. https:\/\/doi.org\/10.1159\/000322497","journal-title":"Eur Neurol"},{"issue":"5","key":"10520_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/jnnp-2017-316625","volume":"89","author":"T Imai","year":"2018","unstructured":"Imai T, Utsugisawa K, Murai H, Tsuda E, Nagane Y, Suzuki Y, Minami N, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Akaishi T, Aoki M (2018) Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry 89(5):513\u2013517. https:\/\/doi.org\/10.1136\/jnnp-2017-316625","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"10520_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, Nakamura Y, Kawaguchi N, Onodera H, Araga S, Isobe N, Nagai M, Kira J (2011) Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 305(1\u20132):97\u2013102. https:\/\/doi.org\/10.1016\/j.jns.2011.03.004","journal-title":"J Neurol Sci"},{"issue":"6","key":"10520_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1046\/j.1468-1331.2003.00678.x","volume":"10","author":"F Romi","year":"2003","unstructured":"Romi F, Gilhus NE, Varhaug JE, Myking A, Aarli JA (2003) Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 10(6):701\u2013706. https:\/\/doi.org\/10.1046\/j.1468-1331.2003.00678.x","journal-title":"Eur J Neurol"},{"issue":"6","key":"10520_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB (2016) Factors affecting outcome in myasthenia gravis. Muscle Nerve 54(6):1041\u20131049. https:\/\/doi.org\/10.1002\/mus.25205","journal-title":"Muscle Nerve"},{"issue":"11","key":"10520_CR17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","volume":"264","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang S, Xi J, Li W, Zhou L, Lu J, Lu J, Zhang T, Zhao C (2017) Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. J Neurol 264(11):2191\u20132200. https:\/\/doi.org\/10.1007\/s00415-017-8616-7","journal-title":"J Neurol"},{"issue":"12","key":"10520_CR18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O\u2019Brien F, Wang JJ, Mantegazza R (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/s1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"6","key":"10520_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, Duda PW, Kaminski HJ (2019) Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. Muscle Nerve 60(6):707\u2013715. https:\/\/doi.org\/10.1002\/mus.26695","journal-title":"Muscle Nerve"},{"issue":"7","key":"10520_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1468-1331.2010.03017.x","volume":"17","author":"ZF Mao","year":"2010","unstructured":"Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC (2010) Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 17(7):913\u2013921. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03017.x","journal-title":"Eur J Neurol"},{"issue":"5","key":"10520_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mus.24438","volume":"51","author":"T Imai","year":"2015","unstructured":"Imai T, Suzuki S, Tsuda E, Nagane Y, Murai H, Masuda M, Konno S, Suzuki Y, Nakane S, Fujihara K, Suzuki N, Utsugisawa K (2015) Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve 51(5):692\u2013696. https:\/\/doi.org\/10.1002\/mus.24438","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10520-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T13:56:26Z","timestamp":1632491786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10520-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10520"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10520-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no financial or other conflicts of interest. All authors report no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The ethics committee of our institute approved this study (IRB No. 2266). The investigation conforms to the principles outlined in the Declaration of Helsinki in relation to the ethical principles for medical research involving human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}